118 related articles for article (PubMed ID: 38436699)
21.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract][Full Text] [Related]
22. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
[TBL] [Abstract][Full Text] [Related]
23. Quantitative parameters in novel spectral computed tomography: Assessment of Ki-67 expression in patients with gastric adenocarcinoma.
Mao LT; Chen WC; Lu JY; Zhang HL; Ye YS; Zhang Y; Liu B; Deng WW; Liu X
World J Gastroenterol; 2023 Mar; 29(10):1602-1613. PubMed ID: 36970586
[TBL] [Abstract][Full Text] [Related]
24. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
26. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Ahn S; Kim KM
Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
30. A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC.
Chen M; Lu H; Copley SJ; Han Y; Logan A; Viola P; Cortellini A; Pinato DJ; Power D; Aboagye EO
J Thorac Oncol; 2023 Jun; 18(6):718-730. PubMed ID: 36773776
[TBL] [Abstract][Full Text] [Related]
31. Association between PD-L1 expression and
Choi YJ; Jo K; Hwang SH; Jeong Y; Lee JY; Kim S; Kim SW; Kim YT; Kang WJ
Ann Nucl Med; 2021 Apr; 35(4):415-420. PubMed ID: 33656683
[TBL] [Abstract][Full Text] [Related]
32. Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
Hu B; Xiao J; Xiu Y; Fu Z; Shi H; Cheng D
Nucl Med Commun; 2020 Mar; 41(3):252-259. PubMed ID: 32068670
[TBL] [Abstract][Full Text] [Related]
33. Is there any correlation between spectral CT imaging parameters and PD-L1 expression of lung adenocarcinoma?
Chen ML; Shi AH; Li XT; Wei YY; Qi LP; Sun YS
Thorac Cancer; 2020 Feb; 11(2):362-368. PubMed ID: 31808285
[TBL] [Abstract][Full Text] [Related]
34. Detection of gastric cancer and its histological type based on iodine concentration in spectral CT.
Li R; Li J; Wang X; Liang P; Gao J
Cancer Imaging; 2018 Nov; 18(1):42. PubMed ID: 30413174
[TBL] [Abstract][Full Text] [Related]
35. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
36. Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer.
Liu KH; Yang W; Tian HP
Clin Radiol; 2024 Feb; 79(2):e264-e272. PubMed ID: 37926648
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
38. Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression.
Toyokawa G; Takada K; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Nov; 18(6):e375-e383. PubMed ID: 28385373
[TBL] [Abstract][Full Text] [Related]
39. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
40. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors.
Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB
Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
